Solute Carrier Family 1 Member 5 (SLC1A5)-dependent glutamine transport regulates macrophage senescence and efferocytosis during liver regeneration.
Key claim: In a mouse partial-hepatectomy model, macrophage SLC1A5-dependent glutamine uptake prevents senescence and preserves Gas6-mediated efferocytosis required for liver regeneration, and glutamine supplementation or senolytic quercetin rescues defective regeneration.
Abstract
The liver possesses an extraordinary capacity to regenerate after injury or surgical resection, a process highly dependent on the coordinated orchestration of the immune microenvironment. Although macrophages are recognized as pivotal coordinators of hepatic tissue repair, the precise checkpoints governing their functional transitions during regeneration remain elusive. Here, we identify the glutamine transporter SLC1A5 (Solute Carrier Family 1 Member 5) as a critical metabolic gatekeeper of macrophage function during liver regeneration. Using a mouse model of partial hepatectomy, we show that SLC1A5 is markedly upregulated in monocyte-derived macrophages at the peak of regeneration. Myeloid specific deletion of Slc1a5 (Slc1a5Lyz2) severely impairs hepatocyte proliferation and diminishes the expression of macrophage derived regenerative factors. Mechanistically, Slc1a5 deficiency depletes intracellular glutamine, which triggers macrophage senescence and drives a pro-inflammatory phenotype. This senescent state selectively downregulates Gas6 (Growth Arrest Specific 6), a crucial bridging ligand for efferocytosis, thereby impairing apoptotic cell clearance and exacerbating local inflammation. Strikingly, exogenous Gas6, senolytic Quercetin therapy, or in vivo L-glutamine supplementation successfully alleviates macrophage senescence, reinstates Gas6 mediated efferocytosis, and rescues defective liver regeneration. Collectively, our findings reveal a novel ‘Slc1a5-glutamine-senescence-efferocytosis’ axis that dictates macrophage driven tissue repair. This study not only uncovers a fundamental immunometabolic mechanism but also highlights glutamine supplementation and senolytics therapy as promising clinically strategies to accelerate liver regeneration.
Why this matters
This finding threads a specific amino-acid transporter (SLC1A5) through macrophage senescence and efferocytosis to a functional regenerative outcome (liver regrowth after partial hepatectomy), giving the senescence-drives-tissue-dysfunction narrative a concrete metabolic entry point rather than a generic SASP story. The rescue by glutamine or quercetin sits squarely in the preclinical senolytic paradigm, but the human-translation gap remains wide — a mouse resection model is not a chronic-aging or human-regeneration readout.